A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess

Yan W. Chen, Yao Shen Chen, S. S J Lee, Muh Yong Yen, Shue R. Wann, Hsi Hsun Lin, Wen Kuei Huang, Yung Ching Liu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The object of this open-label, randomized, comparative study was to evaluate the efficacy and safety of fleroxacin versus conventional therapy (cefazolin plus gentamicin/cephalexin) in the treatment of patients with bacterial liver abscess. Thirty-one adult patients (26 men and 5 women) received fleroxacin 400 mg orally once daily for 3 weeks, and 30 adult patients (21 men and 9 women) received conventional therapy for 3 to 4 weeks. Patients was assessed on day 3 of treatment, thereafter every week during treatment, and at 7 to 14 days (compulsory follow-up) after treatment for assessment of bacteriologic, clinical, and safety parameters. A total of 20 patients in the fleroxacin group and 22 patients in the conventional therapy group were evaluated. Klebsiella pneumoniae was the predominant pathogen isolated in all evaluable cases. Bacteriologic cure was achieved in 14 (70%) of 20 patients on fleroxacin therapy compared with 18 (81.8%) of 22 patients on conventional therapy (p=0.48). Clinical cure was achieved in 12 (60%) and 18 (81.8%) patients, and improvement in 2 (10%) and 1 (4.5%) patients in the fleroxacin and conventional therapy group, respectively. Most of adverse effects were of mild intensity. Oral fleroxacin once-daily administration is an effective, alternative treatment of bacterial liver abscess.

Original languageEnglish
Pages (from-to)179-183
Number of pages5
JournalJournal of Microbiology, Immunology and Infection
Volume35
Issue number3
Publication statusPublished - Sep 2002
Externally publishedYes

Fingerprint

Fleroxacin
Pyogenic Liver Abscess
Therapeutics
Liver Abscess
Group Psychotherapy
Cephalexin
Safety
Cefazolin
Klebsiella pneumoniae
Gentamicins

Keywords

  • Bacterial liver abscess
  • Clinical trial
  • Fleroxacin
  • Klebsiella pneumoniae

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess. / Chen, Yan W.; Chen, Yao Shen; Lee, S. S J; Yen, Muh Yong; Wann, Shue R.; Lin, Hsi Hsun; Huang, Wen Kuei; Liu, Yung Ching.

In: Journal of Microbiology, Immunology and Infection, Vol. 35, No. 3, 09.2002, p. 179-183.

Research output: Contribution to journalArticle

Chen, Yan W. ; Chen, Yao Shen ; Lee, S. S J ; Yen, Muh Yong ; Wann, Shue R. ; Lin, Hsi Hsun ; Huang, Wen Kuei ; Liu, Yung Ching. / A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess. In: Journal of Microbiology, Immunology and Infection. 2002 ; Vol. 35, No. 3. pp. 179-183.
@article{a77f191a077d4f429483dcb6ba46c0de,
title = "A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess",
abstract = "The object of this open-label, randomized, comparative study was to evaluate the efficacy and safety of fleroxacin versus conventional therapy (cefazolin plus gentamicin/cephalexin) in the treatment of patients with bacterial liver abscess. Thirty-one adult patients (26 men and 5 women) received fleroxacin 400 mg orally once daily for 3 weeks, and 30 adult patients (21 men and 9 women) received conventional therapy for 3 to 4 weeks. Patients was assessed on day 3 of treatment, thereafter every week during treatment, and at 7 to 14 days (compulsory follow-up) after treatment for assessment of bacteriologic, clinical, and safety parameters. A total of 20 patients in the fleroxacin group and 22 patients in the conventional therapy group were evaluated. Klebsiella pneumoniae was the predominant pathogen isolated in all evaluable cases. Bacteriologic cure was achieved in 14 (70{\%}) of 20 patients on fleroxacin therapy compared with 18 (81.8{\%}) of 22 patients on conventional therapy (p=0.48). Clinical cure was achieved in 12 (60{\%}) and 18 (81.8{\%}) patients, and improvement in 2 (10{\%}) and 1 (4.5{\%}) patients in the fleroxacin and conventional therapy group, respectively. Most of adverse effects were of mild intensity. Oral fleroxacin once-daily administration is an effective, alternative treatment of bacterial liver abscess.",
keywords = "Bacterial liver abscess, Clinical trial, Fleroxacin, Klebsiella pneumoniae",
author = "Chen, {Yan W.} and Chen, {Yao Shen} and Lee, {S. S J} and Yen, {Muh Yong} and Wann, {Shue R.} and Lin, {Hsi Hsun} and Huang, {Wen Kuei} and Liu, {Yung Ching}",
year = "2002",
month = "9",
language = "English",
volume = "35",
pages = "179--183",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "0253-2662",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess

AU - Chen, Yan W.

AU - Chen, Yao Shen

AU - Lee, S. S J

AU - Yen, Muh Yong

AU - Wann, Shue R.

AU - Lin, Hsi Hsun

AU - Huang, Wen Kuei

AU - Liu, Yung Ching

PY - 2002/9

Y1 - 2002/9

N2 - The object of this open-label, randomized, comparative study was to evaluate the efficacy and safety of fleroxacin versus conventional therapy (cefazolin plus gentamicin/cephalexin) in the treatment of patients with bacterial liver abscess. Thirty-one adult patients (26 men and 5 women) received fleroxacin 400 mg orally once daily for 3 weeks, and 30 adult patients (21 men and 9 women) received conventional therapy for 3 to 4 weeks. Patients was assessed on day 3 of treatment, thereafter every week during treatment, and at 7 to 14 days (compulsory follow-up) after treatment for assessment of bacteriologic, clinical, and safety parameters. A total of 20 patients in the fleroxacin group and 22 patients in the conventional therapy group were evaluated. Klebsiella pneumoniae was the predominant pathogen isolated in all evaluable cases. Bacteriologic cure was achieved in 14 (70%) of 20 patients on fleroxacin therapy compared with 18 (81.8%) of 22 patients on conventional therapy (p=0.48). Clinical cure was achieved in 12 (60%) and 18 (81.8%) patients, and improvement in 2 (10%) and 1 (4.5%) patients in the fleroxacin and conventional therapy group, respectively. Most of adverse effects were of mild intensity. Oral fleroxacin once-daily administration is an effective, alternative treatment of bacterial liver abscess.

AB - The object of this open-label, randomized, comparative study was to evaluate the efficacy and safety of fleroxacin versus conventional therapy (cefazolin plus gentamicin/cephalexin) in the treatment of patients with bacterial liver abscess. Thirty-one adult patients (26 men and 5 women) received fleroxacin 400 mg orally once daily for 3 weeks, and 30 adult patients (21 men and 9 women) received conventional therapy for 3 to 4 weeks. Patients was assessed on day 3 of treatment, thereafter every week during treatment, and at 7 to 14 days (compulsory follow-up) after treatment for assessment of bacteriologic, clinical, and safety parameters. A total of 20 patients in the fleroxacin group and 22 patients in the conventional therapy group were evaluated. Klebsiella pneumoniae was the predominant pathogen isolated in all evaluable cases. Bacteriologic cure was achieved in 14 (70%) of 20 patients on fleroxacin therapy compared with 18 (81.8%) of 22 patients on conventional therapy (p=0.48). Clinical cure was achieved in 12 (60%) and 18 (81.8%) patients, and improvement in 2 (10%) and 1 (4.5%) patients in the fleroxacin and conventional therapy group, respectively. Most of adverse effects were of mild intensity. Oral fleroxacin once-daily administration is an effective, alternative treatment of bacterial liver abscess.

KW - Bacterial liver abscess

KW - Clinical trial

KW - Fleroxacin

KW - Klebsiella pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=0036745115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036745115&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 179

EP - 183

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 0253-2662

IS - 3

ER -